LifeSci Capital analyst Charles Zhu maintained a Buy rating on Molecular Partners today and set a price target of $12.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Charles Zhu has given his Buy rating due to a combination of factors, including steady execution on Molecular Partners’ lead radiotherapeutic, MP0712, and clear visibility toward key 2026 catalysts. The company is expanding clinical site activation, remains on schedule for initial SCLC data next year, and management sees room for accelerated dose escalation that could showcase safety and early efficacy signals.
Zhu also highlights the emerging pipeline value from MP0726 and the 225Ac program, where the DARPin platform offers flexibility to explore multiple isotopes and new targets by mid-2026. With roughly $100M in cash providing runway into late 2027, he views the balance sheet as sufficient to reach these data readouts, supporting an unchanged $12 price target and reinforcing his constructive outlook on the stock.